13F Holdings
中文EN

ARQT Arcutis Biotherapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1787306 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY60.0%
TTM net income YoY167.5%
TTM EPS YoY164.7%
Revenue 3-yr CAGR118.1%
Net income 3-yr CAGR—

Margins

Gross margin91.2%
Operating margin6.9%
Net margin5.9%
FCF margin11.7%
EBITDA margin—

Returns

ROE14.9%
ROA6.7%
ROIC (approx.)10.3%
Asset turnover1.14x

Leverage & solvency

Liabilities / assets53.5%
Debt / equity0.45x
Current ratio2.92x
Interest coverage2.56x

Cash quality & payout

Operating cash flow / net income2.00x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$376.07M$196.54M$59.61M$3.69M$0
Cost of revenue$36.70M$19.13M$4.99M$754,000$0
Gross profit$339.38M$177.41M$54.62M$2.93M$0
R&D expense$77.05M$76.42M$110.58M$182.44M$145.56M
SG&A expense$274.55M$229.39M$185.15M$122.12M$60.97M
Operating income-$12.23M-$128.40M-$241.10M-$301.63M-$206.53M
Interest expense$12.08M$27.17M$29.71M$15.65M$0
Pretax income-$8.24M-$130.37M-$255.65M-$311.46M-$206.36M
Income tax$1.17M$647,000$3.11M$0$0
Net income-$16.14M-$140.04M-$262.14M-$311.46M-$206.36M
EBITDA-$11.53M-$127.80M-$240.30M-$301.00M-$206.07M
EPS (basic)-0.13-1.16-3.78-5.66-4.18
EPS (diluted)-0.13-1.16-3.78-5.66-4.18
Weighted avg. shares (diluted)127.23M120.96M69.31M55.03M49.41M
Balance sheet
Cash & equivalents$42.91M$71.95M$89.32M$54.88M$97.99M
Short-term investments$178.07M$156.62M$183.46M$355.95M$290.61M
Receivables$146.23M$73.07M$25.81M$8.46M$0
Inventory$22.63M$14.53M$13.13M$7.51M$0
Current assets$411.23M$335.82M$330.43M$437.41M$402.77M
PP&E, net$1.04M$1.04M$1.54M$1.88M$2.26M
Intangibles$14.81M$9.48M$6.44M$7.19M$0
Total assets$432.97M$348.89M$341.37M$449.27M$408.15M
Current liabilities$129.84M$81.01M$46.67M$37.81M$33.33M
Short-term debt$1.00M$0$0——
Long-term debt$107.96M$107.20M$201.80M$197.77M$72.35M
Total debt$108.96M$107.20M$201.80M$197.77M$72.35M
Total liabilities$243.49M$191.35M$252.70M$239.69M$110.47M
Shareholders' equity$189.48M$157.54M$88.67M$209.58M$297.68M
Net debt$66.05M$35.25M$112.48M$142.89M-$25.64M
Shares outstanding123.33M117.85M96.79M61.04M50.26M
Cash flow statement
Operating cash flow-$5.62M-$112.16M-$247.06M-$257.71M-$174.63M
Capital expenditure$686,000$143,000$428,000$333,000$995,000
Free cash flow-$6.31M-$112.30M-$247.49M-$258.05M-$175.62M
Investing cash flow-$30.25M$28.82M$180.23M-$87.20M-$75.95M
Financing cash flow$6.97M$66.20M$101.32M$301.80M$281.95M
Depreciation & amortization$700,000$600,000$800,000$622,000$454,000
Stock-based compensation$40.36M$41.73M$38.81M$32.68M$23.89M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.